Description

Sailong Pharmaceutical Group Co., Ltd. is a comprehensive Chinese pharmaceutical company dedicated to the research, development, manufacturing, sales, and service of pharmaceutical intermediates, active pharmaceutical ingredients, and finished drug preparations. The firm's extensive product portfolio features compounds such as esomeprazole sodium, ornithine aspartate, thymus extracts, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium. These offerings address a broad spectrum of medical needs, including cardiovascular, cerebrovascular, and neurological disorders, digestive system ailments, as well as acting as proton pump inhibitors, anti-infectives, anti-bleeding medications, and pain relievers, among other therapeutic applications. Established in 2002, the company is headquartered in Zhuhai, China. It operated as Zhuhai Sailong Pharmaceutical Co., Ltd. until September 2021, when it adopted its present name.